Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D03FLT
|
|||
Former ID |
DIB005141
|
|||
Drug Name |
CP-331684
|
|||
Synonyms |
2-[4-[2-[2(R)-(6-Amino-3-pyridinyl)-2-hydroxyethylamino]ethoxy]phenyl]acetic acid
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Diabetic complication [ICD-11: 5A2Y; ICD-9: 253.5, 588.1] | Phase 2 | [1] | |
Structure |
Download2D MOL |
|||
Formula |
C17H21N3O4
|
|||
Canonical SMILES |
C1=CC(=CC=C1CC(=O)O)OCCNCC(C2=CN=C(C=C2)N)O
|
|||
InChI |
1S/C17H21N3O4/c18-16-6-3-13(10-20-16)15(21)11-19-7-8-24-14-4-1-12(2-5-14)9-17(22)23/h1-6,10,15,19,21H,7-9,11H2,(H2,18,20)(H,22,23)/t15-/m0/s1
|
|||
InChIKey |
GZJZZQHTBTUBEL-HNNXBMFYSA-N
|
|||
CAS Number |
CAS 207922-70-1
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Adrenergic receptor beta-3 (ADRB3) | Target Info | Agonist | [2] |
KEGG Pathway | Calcium signaling pathway | |||
cGMP-PKG signaling pathway | ||||
Neuroactive ligand-receptor interaction | ||||
Endocytosis | ||||
Salivary secretion | ||||
Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
Beta3 adrenergic receptor signaling pathway | ||||
Reactome | Adrenoceptors | |||
G alpha (s) signalling events | ||||
WikiPathways | Monoamine GPCRs | |||
Calcium Regulation in the Cardiac Cell | ||||
GPCRs, Class A Rhodopsin-like | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013231) | |||
REF 2 | CN patent application no. 1717230, Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.